JNJ 63823539

Drug Profile

JNJ 63823539

Alternative Names: JNJ63823539

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Covagen
  • Developer Cilag GmbH International; Covagen
  • Class Bispecific antibodies
  • Mechanism of Action Interleukin-17 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis

Most Recent Events

  • 07 Apr 2017 Phase-I clinical trials in Rheumatoid arthritis in Switzerland (SC) before March 2017 )
  • 15 Mar 2017 Phase I clinical trials in Rheumatoid arthritis in Switzerland (IV, infusion) before March 2017
  • 15 Mar 2017 Pharmacokinetics and immunogenicity data from a phase I trial in Rheumatoid arthritis released by Covagen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top